Kate Dyer-Seeley  

I just finished watching The Polio Crusade on PBS’ American Experience.  It’s an incredible documentary, and so relevant to today’s science.  I’ve posted in the past about the lengthy clinical trial process a drug must go through before it hits the market.  At the Alzheimer’s Association we’re working on a marketing plan to encourage people with Alzheimer’s to participate in trials.  These are [...]

The week is coming to a close, wet leaves, pumpkins, and political signs liter my front yard.  The leaves need raking, the pumpkins need carving, and I wish the political signs could be packed away today.  If only we could vote and move on.  Instead, Alzheimer’s research (like so many other important issues) will stall out until next year.  [...]

Dr. Mario Carillo, one of the leading neuroscientists in the field of Alzheimer’s research, spoke last week at the Alzheimer’s Association here in Portland.  Her talk highlighted the top five clinical trials currently in phase three (the last phase a drug must pass before gaining FDA approval).  I consider myself to be fairly well versed in [...]

I spoke at a donor event for the Alzheimer’s Association this evening and got the inside scoop on Dimebon, a drug which just completed its first round of clinic trials.  The drug had been previously used to treat hay fever in Russia.  For  those of you who don’t live across the pond you can read the BBC story here.  [...]

I’ve posted in the past about how imperative it is to support funding to the NIH (National Institute of Health).  A new study funded by the NIH, released earlier this week has isolated a potential causative agent for Alzheimer’s disease.  You can read about the study here.  What’s exciting about this research is it targets a new [...]